Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study by Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, Javier López-Jiménez, Javier de la Rubia, Miquel Granell, Joan Besalduch, Luis Palomera, Yolanda González, Mª Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel T. Hernández, Felipe de Arriba, Norma C. Gutiérrez, Mª Luisa Martín-Ramos, Mª Teresa Cibeira, Mª Victoria Mateos, Joaquín Martínez, Adrián Alegre, Juan José Lahuerta, Jesús San Miguel, and Joan Bladé Blood Volume 120(8):1589-1596 August 23, 2012 ©2012 by American Society of Hematology
PFS according to treatment arm (VTD vs TD vs VBMCP/VBAD/B). Laura Rosiñol et al. Blood 2012;120:1589-1596 ©2012 by American Society of Hematology
OS according to treatment arm. OS according to treatment arm. The estimated OS at 4 years was 74% for VTD, 70% for VBMCP/VBAD/B, and 65% for TD (P = NS). Laura Rosiñol et al. Blood 2012;120:1589-1596 ©2012 by American Society of Hematology
PFS in patients with low- and high-risk cytogenetics. Laura Rosiñol et al. Blood 2012;120:1589-1596 ©2012 by American Society of Hematology
OS in patients with low- and high-risk cytogenetics. Laura Rosiñol et al. Blood 2012;120:1589-1596 ©2012 by American Society of Hematology
OS from progression according to the cytogenetic risk. Laura Rosiñol et al. Blood 2012;120:1589-1596 ©2012 by American Society of Hematology